These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37117056)
1. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers. Nugent C; Abul Y; White EM; Shehadeh F; Kaczynski M; Oscar Felix L; Ganesan N; Oyebanji OA; Vishnepolskiy I; Didion EM; Paxitzis A; Sheehan ML; Chan PA; Pfeifer WM; Dickerson E; Kamojjala S; Wilson BM; Mylonakis E; King CL; Balazs AB; Canaday DH; Gravenstein S Vaccine; 2023 May; 41(22):3403-3409. PubMed ID: 37117056 [TBL] [Abstract][Full Text] [Related]
2. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers. Nugent C; Abul Y; White E; Shehadeh F; Kaczynski M; Felix LO; Ganesan N; Oyebanji OA; Vishnepolskiy I; Didion EM; Paxitzis A; Sheehan ML; Mylonakis E; Wilson BM; Balazs AB; Chan PA; King CL; Pfeifer WM; Dickerson E; Canaday DH; Gravenstein S medRxiv; 2023 Jan; ():. PubMed ID: 36747765 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022. Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254 [TBL] [Abstract][Full Text] [Related]
4. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871 [TBL] [Abstract][Full Text] [Related]
5. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents. Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB medRxiv; 2024 Mar; ():. PubMed ID: 38585784 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S EBioMedicine; 2022 Jun; 80():104066. PubMed ID: 35605428 [TBL] [Abstract][Full Text] [Related]
7. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals. Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022. McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757 [TBL] [Abstract][Full Text] [Related]
9. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH; Saini M; Wieland A; Manning KE; Ellis M; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Edara VV; Patel M; Steur C; Nooka AK; Green F; Johns MA; O'Brein F; Shanmugasundaram U; Zarnitsyna VI; Ahmed H; Nyhoff LE; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar MS; Dhodapkar MV; Ramalingam S; Ahmed R J Clin Oncol; 2022 Nov; 40(33):3808-3816. PubMed ID: 35759727 [TBL] [Abstract][Full Text] [Related]
10. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice. Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022. Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708 [TBL] [Abstract][Full Text] [Related]
12. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents. Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933 [TBL] [Abstract][Full Text] [Related]
14. Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination. Gravenstein S; DeVone F; Oyebanji OA; Abul Y; Cao Y; Chan PA; Halladay CW; Rudolph JL; Nugent C; Bosch J; King CL; Wilson BM; Balazs AB; White EM; Canaday DH; McConeghy KW EBioMedicine; 2024 Jul; 105():105180. PubMed ID: 38861869 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection. Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D; J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782 [TBL] [Abstract][Full Text] [Related]
16. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5. Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738 [TBL] [Abstract][Full Text] [Related]
19. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals. Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601 [TBL] [Abstract][Full Text] [Related]
20. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers. Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]